AACC 2018 Chicago

AACC is AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY. AACC 2018 is organizing their 70th Annual Scientific Meeting from 29 July to 2 Aug. AACC The outstanding event in Medical and Chemistry category will be the center of attention to Laboratory Management, Mass Spectrometry, Clinical Chemistry, Molecular Diagnostics, Laboratory Medicine and Translational Medicine areas. American Association for…

MEDLAB Dubai, 2018 – NGeneBio at Z6.A31

Booth Stand No. Z6.A31 https://www.medlabme.com/en/overview/show-information.html <Show Information> 600 EXHIBITORS 40 EXHIBITING COUNTRIES 16 COUNTRY PAVILIONS 25,000 ATTENDEES 6,500 DELEGATES 17 CONFERENCES MEDLAB is the flagship exhibition and congress of the MEDLAB Series portfolio, a collection of leading laboratory and diagnostics exhibitions and conferences worldwide, spanning across the Middle East, Asia, East/West Africa, Europe and the…

NGeneBio Receives CE Mark for BRCA Test Panel and Data Analysis Software

NGeneBio Receives CE Mark for BRCA Test Panel and Data Analysis Software Regulatory Roundup: September 2017 Date: SEP.1.2017  // Source: Clinical Laboratory News Topics:  Cancer and Tumors, Genetics and Genomics Disorders, Government and Regulatory NGeneBio, a molecular diagnostics startup based in Seoul, South Korea, received the CE mark for BRCAaccuTest and NGeneAnalySys, two next-generation sequencing (NGS) based products that…

Korean IVD startup NGeneBio receives CE-IVD mark for next generation sequencing-based BRCA 1/2 test panel and clinical analysis software

SEOUL, South Korea, July 6, 2017 /PRNewswire/ — Molecular diagnostics startup NGeneBio Co., Ltd. of Korea has received CE-marking for next generation sequencing (NGS)-based in vitro diagnostics (IVD) products, BRCAaccuTestTM and clinical analysis software, NGeneAnalySysTM for hereditary breast/ovarian cancer genetic testing (30/Jun). BRCAaccuTestTM is an amplicon-based targeted NGS panel which detects germline mutations in BRCA1…

NGeneBio Garners CE-IVD Mark for NGS BRCA Test

NEW YORK (GenomeWeb) – NGeneBio, a Korean molecular diagnostics startup, said today that it has achieved a CE-IVD mark for its BRCAaccuTest and clinical analysis software. Seoul-based NGeneBio said the amplicon-based, targeted next-generation sequencing panel can be used to detect mutations in the BRCA1 and BRCA2 genes associated with predisposition to breast and ovarian cancers.…